.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Claims for Patent: 7,163,931

« Back to Dashboard

Claims for Patent: 7,163,931

Title:Compositions of estrogen-cyclodextrin complexes
Abstract:Pharmaceutical compositions comprising low doses of sensitive complexes between an estrogen and a cyclodextrin are provided with improved stability. In specific embodiments the composition comprises a complex between ethinyl estradiol and .beta.-cyclodextrin in a granulate preparation and in yet another embodiment the composition comprises a limited amount of polyvinylpyrrolidone since this excipient was found to degrade ethinyl estradiol. Furthermore, a method for improving the stability of an estrogen in a composition and for manufacturing such a stable composition is provided. Essentially, the granulate preparation are manufactured under careful control of the relative humidity.
Inventor(s): Backensfeld; Thomas (Berlin, DE), Heil; Wolfgang (Berlin, DE), Lipp; Ralph (Berlin, DE)
Assignee: Schering Aktiengesellchaft (Berlin, DE)
Application Number:11/102,681
Patent Claims: 1. A method for inhibiting ovulation in a female comprising administering to the female a composition comprising: i) a complex between an estrogen and a cyclodextrin; ii) drospirenone; and iii) one or more excipients, the composition having a stability such that said estrogen is in amount of at least 85% w/w in relation to the initial content of said estrogen after storage for 12 months at 40.degree. C. and 75% relative humidity (RH).

2. The method of claim 1, wherein the complex between an estrogen and a cyclodextrin is a granulate preparation having a relative humidity of at most 60%, as determined at a temperature between 20.degree. C. and 40.degree. C.

3. The method of claim 1, wherein the estrogen is in an amount corresponding to a therapeutically equivalent amount of ethinyl estradiol of from about 0.002% w/w to 2% w/w, based on the total composition.

4. The method of claim 1, wherein the estrogen is in an amount from about 0.002% w/w to 2% w/w, based on the total composition.

5. The method of claim 1, wherein the estrogen is in an amount from about 0.004% w/w to 0.2% w/w, based on the total composition.

6. The method of claim 1, wherein the estrogen is ethinyl estradiol and the cyclodextrin is .beta.-cyclodextrin, and the ethinyl estradiol is in an amount relative to the ethinyl-estradiol-.beta.-cyclodextrin complex of from about 5% w/w to 20% w/w.

7. The method of claim 1, wherein the estrogen is ethinyl estradiol and the cyclodextrin is .beta.-cyclodextrin, and the ethinyl estradiol is in an amount relative to the ethinyl-estradiol-.beta.-cyclodextrin complex of from about 8% w/w to 15% w/w.

8. The method of claim 1, wherein the amount of drospirenone is from about 0.4% to 20% w/w.

9. The method of claim 1, wherein the amount of drospirenone is from about 0.8% w/w to 10% w/w, based on the total composition.

10. The method of claim 1, wherein the amount of drospirenone is from about 1.5% w/w to 5% w/w, based on the total composition.

11. The method of claim 1, wherein the one or more excipients comprises polyvinylpyrrolidone in an amount of at most 2% w/w.

12. The method according to claim 1, wherein the one or more excipients comprises polyvinylpyrrolidone in an amount of at most 1% w/w.

13. The method according to claim 1, wherein the one or more excipients comprises polyvinylpyrrolidone in ah amount of at most 0.5% w/w.

14. The method according to claim 1, wherein the one or more excipients comprises polyvinylpyrrolidone in an amount of at most 0.2% w/w.

15. The method according to claim 1, wherein the composition is essentially free of polyvinylpyrrolidone.

16. The method according to claim 1, wherein the composition comprises one or more excipient(s) which is/are selected from the group consisting of starch, cellulose, hydroxypropylcellulose, hydroxypropylmethylcellulose and maltodextrin.

17. The method according to claim 1, wherein the estrogen in the composition is selected from the group consisting of ethinyl estradiol, estradiol, estradiol sulfamates, estradiol valerate, estradiol benzoate, estrone, estrone sulfate and mixtures thereof.

18. The method according to claim 1, wherein the estrogen is ethinyl estradiol.

19. The method according to claim 1, wherein the cyclodextrin is selected from the group consisting of .alpha.-cyclodextrin, .beta.-cyclodextrin, .gamma.-cyclodextrin and alkylated or acylated derivatives thereof.

20. The method according to claim 1, wherein the cyclodextrin is .beta.-cyclodextrin or an alkylated or acylated derivative thereof.

21. The method according to claim 1, wherein the estrogen is in an amount relative to the cyclodextrin such that a molar ratio between the estrogen and the cyclodextrin is from about 2:1 to 1:10.

22. The method according to claim 1, wherein the drospirenone is in micronized form.

23. The method according to claim 1, wherein the complex between an estrogen and a cyclodextrin is micronized.

24. The method according to claim 1, wherein the composition further comprises an antioxidant.

25. The method according to claim 1, wherein the granulated preparation has a mean particle size of at least about 100 .mu.m.

26. The method of claim 1, wherein the composition has a stability such that said estrogen is in an amount of at least 90% w/w in relation to the initial content of said estrogen after storage for 12 months at 40.degree. C. and 75% relative humidity (RH).

27. A method for hormone replacement therapy in a female comprising administering to the female a composition comprising: i) a complex between an estrogen and a cyclodextrin; ii) drospirenone; and iii) one or more excipients, the composition having a stability such that said estrogen is in amount of at least 85% w/w in relation to the initial content of said estrogen after storage for 12 months at 40.degree. C. and 75% relative humidity (RH).

28. The method of claim 27, wherein the complex between an estrogen and a cyclodextrin is a granulate preparation having a relative humidity of at most 60%, as determined at a temperature between 20.degree. C. and 40.degree. C.

29. The method of claim 27, wherein the estrogen is in an amount corresponding to a therapeutically equivalent amount of ethinyl estradiol of from about 0.002% w/w to 2% w/w, based on the total composition.

30. The method of claim 27, wherein the estrogen is in an amount from about 0.002% w/w to 2% w/w, based on the total composition.

31. The method of claim 27, wherein the estrogen is in an amount from about 0.004% w/w to 0.2% w/w, based on the total composition.

32. The method of claim 27, wherein the estrogen is ethinyl estradiol and the cyclodextrin is .beta.-cyclodextrin, and the ethinyl estradiol is in an amount relative to the ethinyl-estradiol-.beta.-cyclodextrin complex of from about 5% w/w to 20% w/w.

33. The method of claim 27, wherein the estrogen is ethinyl estradiol and the cyclodextrin is .beta.-cyclodextrin, and the ethinyl estradiol is in an amount relative to the ethinyl-estradiol-.beta.-cyclodextrin complex of from about 8% w/w to 15% w/w.

34. The method of claim 27, wherein the amount of drospirenone is from about 0.4% to 20% w/w.

35. The method of claim 27, wherein the amount of drospirenone is from about 0.8% w/w to 10% w/w, based on the total composition.

36. The method of claim 27, wherein the amount of drospirenone is from about 1.5% w/w to 5% w/w, based on the total composition.

37. The method of claim 27, wherein the one or more excipients comprises polyvinylpyrrolidone in an amount of at most 2% w/w.

38. The method according to claim 27, wherein the one or more excipients comprises polyvinylpyrrolidone in an amount of at most 1% w/w.

39. The method according to claim 27, wherein the one or more excipients comprises polyvinylpyrrolidone in an amount of at most 0.5% w/w.

40. The method according to claim 27, wherein the one or more excipients comprises polyvinylpyrrolidone in an amount of at most 0.2% w/w.

41. The method according to claim 27, wherein the composition is essentially free of polyvinylpyrrolidone.

42. The method according to claim 27, wherein the composition comprises one or more excipient(s) which is/are selected from the group consisting of starch, cellulose, hydroxypropylcellulose, hydroxypropylmethylcellulose and maltodextrin.

43. The method according to claim 27, wherein the estrogen in the composition is selected from the group consisting of ethinyl estradiol, estradiol, estradiol sulfamates, estradiol valerate, estradiol benzoate, estrone, estrone sulfate and mixtures thereof.

44. The method according to claim 27, wherein the estrogen is ethinyl estradiol.

45. The method according to claim 27, wherein the cyclodextrin is selected from the group consisting of .alpha.-cyclodextrin, .beta.-cyclodextrin, .gamma.-cyclodextrin and alkylated or acylated derivatives thereof.

46. The method according to claim 27, wherein the cyclodextrin is .beta.-cyclodextrin or an alkylated or acylated derivative thereof.

47. The method according to claim 27, wherein the estrogen is in an amount relative to the cyclodextrin such that a molar ratio between the estrogen and the cyclodextrin is from about 2:1 to 1:10.

48. The method according to claim 27, wherein the drospirenone is in micronized form.

49. The method according to claim 27, wherein the complex between an estrogen and a cyclodextrin is micronized.

50. The method according to claim 27, wherein the composition further comprises an antioxidant.

51. The method according to claim 27, wherein the granulated preparation has a mean particle size of at least about 100 .mu.m.

52. The method of claim 27, wherein the composition has a stability such that said estrogen is in an amount of at least 90% w/w in relation to the initial content of said estrogen after storage for 12 months at 40.degree. C. and 75% relative humidity (RH).
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc